Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356070 | 1.00 | SLC15A2 (0.48) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL2242452 | 0.99 | SLC15A2 (0.48) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL4588257 | 0.99 | SLC15A2 (0.48) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL5969770 | 0.92 | SLC15A2 (0.50) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL1959809 | 0.92 | SLC15A2 (0.50) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL1959812 | 0.92 | SLC15A2 (0.50) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL2811601 | 0.91 | SLC15A2 (0.49) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| Hydrochloric Acid SCHEMBL7805623 | 0.91 | SLC15A2 (0.49) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL4590038 | 0.91 | SLC15A2 (0.49) | SLC15A2CPB2ECE1ERAP2ERAP1 | |
| SCHEMBL2247594 | 0.91 | SLC15A2 (0.49) | SLC15A2CPB2ECE1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026040002-A1 | COMPOSITION AND METHOD FOR CARING FOR THE SKIN | L'OREAL (FR) | 2026-02-26 | — | — | WO | claimed |
| US-20040180102-A1 | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto | PROCYTE CORPORATION | 2004-09-16 | — | — | US | claimed |
| US-5550183-A | Metal-peptide compositions and methods for stimulating hair growth | PROCYTE CORPORATION (US) | 1996-08-27 | — | — | US | claimed |
| WO-2026040002-A1 | COMPOSITION AND METHOD FOR CARING FOR THE SKIN | L'OREAL (FR) | 2026-02-26 | — | — | WO | disclosed |
| WO-2022204461-A1 | KITS, COMPOSITIONS, AND METHODS OF TREATING HAIR LOSS | ANDREWS NICK (US) | 2022-09-29 | — | — | WO | disclosed |
| US-9586989-B1 | Non-toxic skin cancer therapy with copper peptides | SKIN BIOLOGY, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-1998790-B1 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PROD INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2350252-A2 | ANTIMICROBIAL FOAMABLE SOAPS | Ohso Clean, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010059366-A2 | ANTIMICROBIAL FOAMABLE SOAPS | OHSO CLEAN, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | AVON PRODUCTS INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1998790-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007100874-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-7186687-B2 | Compositions and methods for treatment of Psoriasis | PROCYTE CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180102-A1 | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto | HMOX1, HES1, SOD1 | SLC15A2 2820/4885CPB2 3256/4885ECE1 1253/4885 |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | CUTA, NGLY1, LNPEP | SLC15A2 1369/4885CPB2 400/4885ECE1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.